多西他赛联合低剂量顺铂治疗晚期高龄非小细胞肺癌的临床研究

doi:10.3971/j.issn.1000-8578.3223

多西他赛联合低剂量顺铂治疗晚期高龄非小细胞肺癌的临床研究

Cl inical Observation of Docetaxel Combined with Low2dose Cisplatin for Treating Advanced Non2small Cell Lung Cancer in Elderly Patients

摘要

摘要: 目的探讨多西他赛联合低剂量顺铂治疗晚期高龄非小细胞肺癌（NSCLC）的疗效及毒副反应。方法对31例晚期高龄NSCLC患者用多西他赛40mg／m^-2，静脉滴注，每周1次，连续2周；顺铂14mg／m^2，静脉滴注，每天1次，连用5次；以上化疗方案每4周重复1次，每例进行2周期化疗。结果全组31例，总有效率32．3％（10／31），其中PR10例，SD16例，PD5例，无CR病例，中位生存时间10．3个月。Ⅲ～Ⅳ度的中性粒细胞减少发生率为29．0％（9／31），非血液学毒性主要为疲劳乏力等（14／31，占45．2％）。结论周剂量多西他赛联合低剂量顺铂是治疗晚期高龄NSCLC较好的化疗方案

Abstract: Objective 　To evaluated the efficacy and toxicity of Docetaxel combined with low2dose Cisplatin as alternative chemotherapy for elderly patient s with advanced non small cell lung cancer (NSCLC) . Methods 　Thirty2one patient s were enrolled in the study. Each was t reated as following : Docetaxel 40mg/ m2 infusion once per week for two weeks ; Cisplatin 14mg/ m2 / d infusion on day1～5. Af ter 2 con2 secutive t reatment course, each for 4 weeks, evaluation of the short2term efficacy and adverse effect s was carried out . Results 　The overall response rate was 32. 3 %(10/ 31) . CR0 (0 %), PR10 (32. 3 %), SD16 (51. 6 %), PD5 (16. 1 %), median OS was 10. 3 months. Hematologic toxicities, which were mild, in2 cluded grade Ⅲ～ Ⅳ neut ropenia in 29. 0 %(9/ 31) . The major non2hematologic toxicity was weakness (45. 2 %) . Conclusion 　Weekly Docetaxel combined with low2dose Cisplatin as alternative chemotherapy is encouraging for elderly patient s with advanced NSCLC.

HTML全文

参考文献(0)

施引文献

资源附件(0)